SVB Securities downgraded Halozyme to Market Perform from Outperform with a $42 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HALO:
- Halozyme price target lowered to $55 from $65 at Wells Fargo
- Halozyme reaffirms FY23 revenue view $815M-$845M, consensus $829.01M
- Halozyme provides update on EPO decision regarding Darzalex
- Halozyme director Henderson sells 20,000 common shares
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS